An analysis of ctDNA testing for early detection of recurrence showed that test had high sensitivity across multiple sites of ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

Natera has reported the latest data from the Phase III CALGB (Alliance)/SWOG 80702 study, indicating that Signatera, a ...

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, ...

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III ...

We evaluated opioid-sparing effects and rehabilitative results after perioperative celecoxib administration for total knee arthroplasty. Methods: This was a prospective, randomized, observer-blind ...

A recent analysis from a randomized clinical trial conducted by researchers at the Dana-Farber Brigham Cancer Center ...

Luyten and colleagues' prospective, randomized, multicenter, double-blind trial, therefore, compared continuous and intermittent celecoxib for the treatment of OA. All 123 patients had a flare of ...

Nearly a decade after reports first surfaced linking the prescription pain reliever celecoxib (Celebrex) to an increased risk of heart attack, and two years after the American Heart Association ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...